Group items tagged

Objective To help trainees initiate careers in cardiovascular and stroke research while obtaining significant research results under the supervision of a sponsor or mentor; supports individuals before they're ready for some stage of independent research. Science Focus Research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the Congressionally directed FY13 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Research involving human subjects and human anatomical substances is permitted; however, this award may not be used to conduct clinical trials.

This Funding Opportunity Announcement (FOA) encourages applications focused on the use the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. Examples of possible topics are: identification and validation of risk factors for knee and hip OA, including both modifiable and non-modifiable risk factors; utilization of biospecimens in conjunction with research efforts to determine biochemical markers of early and/or progressive disease; analyses of existing OAI data to assess the effectiveness of biobehavioral, pharmacological, and other interventions that subjects use in response to OA pain; determination of predictive role of MRI changes for subsequent radiographic and clinical outcome changes related to development of knee OA; development of novel and efficient tools for analysis of MR images and x rays that can be applied to large numbers of images with high degrees of reproducibility for diagnosis and monitoring of OA-related changes; and research focused on the trajectory of disease including effects on other joint structures such as muscles, ligaments, and bone, with regard to points where interventions could be made, especially for subsets, to reduce OA severity. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and other partners have placed on the use of the OAI resources.

This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. Examples of possible topics are: identification and validation of risk factors for knee and hip OA, including both modifiable and non-modifiable risk factors; utilization of biospecimens in conjunction with research efforts to determine biochemical markers of early and/or progressive disease; analyses of existing OAI data to assess the effectiveness of biobehavioral, pharmacological, and other interventions that subjects use in response to OA pain; determination of predictive role of MRI changes for subsequent radiographic and clinical outcome changes related to development of knee OA; development of novel and efficient tools for analysis of MR images and x rays that can be applied to large numbers of images with high degrees of reproducibility for diagnosis and monitoring of OA-related changes; and research focused on the trajectory of disease including effects on other joint structures such as muscles, ligaments, and bone, with regard to points where interventions could be made, especially for subsets, to reduce OA severity. The publication of this FOA to the research co

As part of its commitment to young investigators in the field of obesity research, TOS will award a number of travel grants of $500 each to attend the annual meeting. The exact number is set each year by the TOS Council. Potential winners will be selected from the ranking of the submitted abstracts and will need only to return a form signed by their institution acknowledging that the winner is either a graduate student or has received a PhD or MD within the past five years.

The purpose of this FOA is to provide support for innovative research into the role of extracellular RNA (exRNA) in the development of alcohol-related diseases and end-organ injuries. As used here, the term exRNA refers to RNA molecules circulating outside of cells, either within vesicles or associated with carrier molecules. It is anticipated that this FOA will generate data that may lead to breakthroughs in our understanding of the role of exRNA communication in the initiation, progression and maintenance of the diverse medical disorders caused by excessive, long-term alcohol consumption. In the future this knowledge may be critical in the diagnosis, treatment and management of vulnerable patient populations debilitated by the vast array of alcohol-induced pathologies and enable clinicians to improve disease outcomes and, consequently, public health. In addition, research supported by this FOA may also provide information on the mechanistic basis of the health benefits of moderate alcohol consumption.

This program (formerly, New Investigator Research Grants) is offered by The Obesity Society (TOS), as a member service, to foster and stimulate new research ideas in any area of investigation related to obesity. The program targets junior-level investigators and post-doctoral trainees by funding proposals that demonstrate a high likelihood of resulting in new and innovative approaches in obesity research. Early-career investigators are defined as individuals who have received a PhD within the past five years or MD within the past eight years and who currently hold full-time, entry-level positions (e.g., post-doctoral fellow, instructor, assistant professor) at an established academic/research institution. Applicants may request up to $25,000. No indirect cost will be paid from this grant. Applications (Letters of Intent) are due April 15, 2013, with funding available September 3, 2013. The award may be expended over a period of up to one year.

Grants of up to $1.62 million over five to seven years will be awarded to support investigators with an innovative basic, clinical, translational, epidemiological, or health services research initiative relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The program seeks to bring new perspectives to diabetes research by offering three types of funding: support for the transition from trainee to independent investigator, support for early-career diabetes investigators, and support for established investigators new to diabetes research.

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.

NOTICE:  Applications are submitted to the American Heart Association via Grants@Heart, a Web-based application system.  Grants@Heart is scheduled to open on May 15, 2013.  In the meantime, please review the program listings, instructions and information in preparation for your application. 

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to perform ancillary studies and secondary analyses of data and/or biospecimens from ongoing or completed studies of the effects of inflammation and/or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline/dementia, and chronic pain. Data that can inform designs of possible future interventional studies on modulating the effects of chronic inflammation in such conditions are of particular interest. Analyses of both beneficial and harmful effects of modulating chronic inflammation in older individuals are of interest. Other types of studies of interest to NIA include mechanistic studies to explore the pathophysiologic processes by which chronic, low-grade inflammation may accelerate functional decline or other geriatric conditions, and how these pathways may be disrupted by interventions. The secondary analyses and ancillary studies supported by this (FOA) may be based on data and/or biospecimens from either ongoing or completed clinical trials.

DARPA is soliciting innovative research proposals of interest to the Defense Sciences Office. Proposed research should investigate innovative approaches that enable revolutionary advances in science and technology. Specifically excluded is research that results primarily in evolutionary improvements to the existing state of the art.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.  Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science. Research results from this FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  

The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.  Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science. Research results from this FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  

The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.  Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science. Research results from this FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.  

The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications to renew an ongoing NIDCD-supported cooperative agreement, the Conservation of Hearing Study (CHEARS).This study will allow continued assessment of preventable risk factors for hearing loss in two large, ongoing, longitudinal cohort studies, the Nurses' Health Studies I and II. 

The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.  

This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the "APOE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.  

This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.